Neoplasms Clinical Trial
Official title:
Effects of a Web Based Education Programme About Sexuality Aimed at Nurses That Care for Patients With Cancer (Sex-Can WebEd Nurse)
Verified date | March 2023 |
Source | Karlstad University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the SexCan - WebEd Nurse study is to evaluate the effect of a five week online university course, "Bring it up - Assessment and support of patients' sexuality in cancer nursing", aimed at cancer nurses, on occupational self-efficacy and attitudes towards addressing sexuality with patients.
Status | Enrolling by invitation |
Enrollment | 18 |
Est. completion date | March 31, 2024 |
Est. primary completion date | March 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Registered nurses working as a contact nurses in cancer care who are admitted to the intervention university course. Exclusion Criteria: - N/A. |
Country | Name | City | State |
---|---|---|---|
Sweden | Karlstad University | Karlstad | Värmland |
Lead Sponsor | Collaborator |
---|---|
Karlstad University |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Occupational Self-Efficacy (from baseline to 5 weeks post finished intervention) | Measured with the "Short Occupational Self-Efficacy Scale". This instrument ranges from 6 to 36 points, where higher values indicate a higher grade of self-efficacy. | At baseline and then 5 weeks post finished intervention. | |
Primary | Change in Occupational Self-Efficacy (from baseline to 19 weeks post finished intervention) | Measured with the "Short Occupational Self-Efficacy Scale" | At baseline and then 19 weeks post finished intervention. | |
Primary | Change in Attitudes towards addressing sexuality (from baseline to 5 weeks post finished intervention) | Measured with the "Sexual Health - Extended Version - Swedish (PASH-Ext-S)". The instrument ranges from 27 to 135 points. Higher values indicate a higher degree of positive attitudes to addressing sexuality. | At baseline and then 5 weeks post finished intervention. | |
Primary | Change in Attitudes towards addressing sexuality (from baseline to 19 weeks post finished intervention) | Measured with the "Sexual Health - Extended Version - Swedish (PASH-Ext-S)" | At baseline and then 19 weeks post finished intervention. | |
Secondary | Change in Knowledge about the influence of cancer on sexuality (from baseline to 5 weeks post finished intervention) | Study specific questionnaire | At baseline and then 5 post finished intervention. | |
Secondary | Change in Knowledge about the influence of cancer on sexuality (from baseline to 19 weeks post finished intervention) | Study specific questionnaire | At baseline and then 19 weeks post finished intervention. | |
Secondary | Change in Number of conversations with patients relating to sexuality (from baseline to 5 weeks post finished intervention) | At baseline and then 5 weeks post finished intervention. | ||
Secondary | Change in Number of conversations with patients relating to sexuality (from baseline to 5 weeks post finished intervention) | At baseline and then 19 weeks post finished intervention. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Completed |
NCT02909348 -
Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab
|